Trial reportThe Journal of urology2026
Comprehensive Evaluation of Targeted and Perilesional Biopsy in Biopsy-Naïve Patients With Prostate Positive Magnetic Resonance Imaging: PERI-PRO Noninferiority Randomized Controlled Trial.
Trial report in The Journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06482658 (Efficacy and Safety Evaluation of Transrectal Perilesional/Regional Systematic Biopsy in Diagnosis of Prostate Cancer), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety Evaluation of Transrectal Perilesional/Regional Systematic Biopsy in Diagnosis of Prostate Cancer: a Randomized Controlled Trial
Who cites it
2 citing papers in PubMed.
- Prostate MRI reporting and its impact on clinical decision-making: the urologists' perspective.Abdominal radiology (New York) · 2026Review
- Pediatric urolithiasis: expanding knowledge and refining minimally invasive management-editorial for the world journal of urology topic collection.World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe combined targeted and systematic biopsy (CTSBx) was the standard scheme for patients with visible suspicious lesions on MRI in recent years. 2024 European Association of Urology guideline recommended targeted and perilesional biopsy (TPLBx) for the diagnosis of patients with MRI-visible suspicious lesions. This randomized controlled trial aims to comprehensively evaluate the efficacy and safety profiles of TPLBx and CTSBx schemes. MATERIALS AND
methodsA single-center noninferiority randomized controlled trial consecutively enrolled 380 biopsy-naïve patients (CTSBx: n = 190, TPLBx: n = 190) with a single unilateral suspicious lesion on prostate MRI from June 2024 to November 2024. The noninferiority margin was -15%. All biopsies were undertaken transrectally through the cognitive fusion technique. The primary outcome was Grade Group (GG) ≥ 2 cancer (GG ≥ 2-PCa) detection rate.
resultsThe GG ≥ 2-PCa (58% vs 58%, risk difference [RD]: 0.53% [95% CI: -9.4% to 11%]) and GG ≥ 3-PCa (30% vs 30%, RD: 0.53% [95% CI: -8.7% to 9.7%]) detection rates of TPLBx were noninferior to that of CTSBx (
conclusionsFor patients with a single unilateral suspicious lesion on prostate MRI, TPLBx achieved the noninferior diagnostic efficacy of clinically significant PCa and better safety than the CTSBx scheme.
trial registrationClinicalTrials.gov Identifier: NCT06482658.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.